These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Enhancement of mitochondrial function correlates with the extension of lifespan by caloric restriction and caloric restriction mimetics in yeast. Choi KM; Lee HL; Kwon YY; Kang MS; Lee SK; Lee CK Biochem Biophys Res Commun; 2013 Nov; 441(1):236-42. PubMed ID: 24141116 [TBL] [Abstract][Full Text] [Related]
31. Efficient synthesis of natural polyphenolic stilbenes: resveratrol, piceatannol and oxyresveratrol. Sun HY; Xiao CF; Cai YC; Chen Y; Wei W; Liu XK; Lv ZL; Zou Y Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1492-6. PubMed ID: 21048342 [TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Chong J; Leung B; Poole P Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692 [TBL] [Abstract][Full Text] [Related]
34. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555 [TBL] [Abstract][Full Text] [Related]
35. Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Wesołowska O; Kuzdzał M; Strancar J; Michalak K Biochim Biophys Acta; 2009 Sep; 1788(9):1851-60. PubMed ID: 19527681 [TBL] [Abstract][Full Text] [Related]
36. Resveratrol and Lifespan in Model Organisms. Pallauf K; Rimbach G; Rupp PM; Chin D; Wolf IM Curr Med Chem; 2016; 23(41):4639-4680. PubMed ID: 27781945 [TBL] [Abstract][Full Text] [Related]
37. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484 [TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782 [TBL] [Abstract][Full Text] [Related]
39. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice. Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141 [TBL] [Abstract][Full Text] [Related]
40. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs. Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D; Mokrý J Exp Lung Res; 2017; 43(9-10):407-416. PubMed ID: 29220595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]